STOCK TITAN

[Form 4] Thermo Fisher Scientific, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Michael D. Shafer, Executive Vice President of Thermo Fisher Scientific, filed a Form 4 disclosing four dispositions of the issuer's common stock on 08/28/2025. Each transaction is reported with Transaction Code F and a per-share price of $489.74. The reported share decreases are 145.051, 162.457, 176.478 and 114.106 shares, leaving a final beneficial ownership of 18,730.8026 shares after the last reported sale. The filing notes inclusion of 49.871 shares acquired under the company employee stock purchase plan on May 15, 2025. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Shafer on 09/02/2025. The document identifies Mr. Shafer as an officer (Executive Vice President) of the issuer.

Michael D. Shafer, Vicepresidente Esecutivo di Thermo Fisher Scientific, ha presentato un Modulo 4 che segnala quattro cessioni di azioni ordinarie dell'emittente in data 08/28/2025. Ciascuna operazione è riportata con Transaction Code F e un prezzo per azione di $489.74. Le diminuzioni segnalate sono di 145.051, 162.457, 176.478 e 114.106 azioni, con una detenzione beneficiaria finale di 18,730.8026 azioni dopo l'ultima vendita. Il documento indica l'inclusione di 49.871 azioni acquisite tramite il piano di acquisto azionario per dipendenti il 15 maggio 2025. Il Modulo 4 è stato firmato da un procuratore (attorney-in-fact) per conto del Sig. Shafer in data 09/02/2025. Il documento identifica il Sig. Shafer come dirigente (Executive Vice President) dell'emittente.

Michael D. Shafer, Vicepresidente Ejecutivo de Thermo Fisher Scientific, presentó un Formulario 4 que revela cuatro enajenaciones de acciones ordinarias del emisor el 08/28/2025. Cada operación figura con Transaction Code F y un precio por acción de $489.74. Las reducciones declaradas son de 145.051, 162.457, 176.478 y 114.106 acciones, dejando una tenencia beneficiaria final de 18,730.8026 acciones tras la última venta informada. La presentación señala la inclusión de 49.871 acciones adquiridas bajo el plan de compra de acciones para empleados el 15 de mayo de 2025. El Formulario 4 fue firmado por un apoderado (attorney-in-fact) en nombre del Sr. Shafer el 09/02/2025. El documento identifica al Sr. Shafer como funcionario (Executive Vice President) del emisor.

Michael D. Shafer, Thermo Fisher Scientific의 총괄 부사장은 08/28/2025자 Form 4를 제출하여 발행사의 보통주 4건의 처분을 공시했습니다. 각 거래는 Transaction Code F로 보고되었고 주당 가격은 $489.74입니다. 보고된 주식 감소량은 각각 145.051, 162.457, 176.478 및 114.106주이며, 마지막 매도 후 최종 실소유지는 18,730.8026주입니다. 서류에는 2025년 5월 15일 직원 주식매입계획으로 취득한 49.871주가 포함되어 있다고 기재되어 있습니다. Form 4는 09/02/2025에 Shafer 씨를 대신해 법정대리인(attorney-in-fact)이 서명했습니다. 문서는 Shafer 씨를 발행사의 임원(Executive Vice President)으로 명시하고 있습니다.

Michael D. Shafer, vice‑président exécutif de Thermo Fisher Scientific, a déposé un Formulaire 4 révélant quatre cessions d'actions ordinaires de l'émetteur le 08/28/2025. Chaque opération est indiquée avec le Transaction Code F et un prix par action de $489.74. Les diminutions signalées sont de 145.051, 162.457, 176.478 et 114.106 actions, laissant une détention bénéficiaire finale de 18,730.8026 actions après la dernière vente déclarée. le dépôt précise l'inclusion de 49.871 actions acquises dans le cadre du plan d'achat d'actions pour salariés le 15 mai 2025. Le Formulaire 4 a été signé le 09/02/2025 par un mandataire (attorney-in-fact) au nom de M. Shafer. Le document identifie M. Shafer comme dirigeant (Executive Vice President) de l'émetteur.

Michael D. Shafer, Executive Vice President von Thermo Fisher Scientific, reichte ein Formular 4 ein, das vier Veräußerungen von Stammaktien des Emittenten am 08/28/2025 offenlegt. Jede Transaktion ist mit Transaction Code F und einem Preis von $489.74 pro Aktie angegeben. Die gemeldeten Aktienminderungen betragen 145.051, 162.457, 176.478 und 114.106 Aktien, wobei nach dem letzten gemeldeten Verkauf ein finaler wirtschaftlicher Besitz von 18,730.8026 Aktien verbleibt. Die Einreichung vermerkt die Einbeziehung von 49.871 Aktien, die am 15. Mai 2025 über den Mitarbeiter-Aktienkaufplan erworben wurden. Das Formular 4 wurde am 09/02/2025 von einem Bevollmächtigten (attorney-in-fact) im Namen von Herrn Shafer unterzeichnet. Das Dokument führt Herrn Shafer als leitenden Angestellten (Executive Vice President) des Emittenten auf.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Officer reported routine share disposals totaling several transactions; filings are compliant and informational.

The Form 4 shows an Executive Vice President reporting four separate dispositions on a single date using Transaction Code F. The filing discloses the post-transaction beneficial ownership levels and a note about shares acquired under the employee stock purchase plan. From a governance standpoint, the disclosure meets Section 16 reporting requirements by identifying the reporting person, relationship to the issuer, transaction dates, codes, and remaining ownership. The signature by an attorney-in-fact is noted and dated.

TL;DR: Multiple small disposals at $489.74 per share were reported; this provides transparency but no clear material signal.

The filing lists four disposals (145.051; 162.457; 176.478; 114.106 shares) at a uniform price of $489.74 on 08/28/2025, leaving 18,730.8026 shares beneficially owned. The Form 4 also documents 49.871 shares from the employee purchase plan acquired May 15, 2025. For investors, the filing supplies exact quantities and prices, enhancing transparency around insider activity. The transactions are presented without additional context about purpose, so they should be interpreted strictly as reported disposals.

Michael D. Shafer, Vicepresidente Esecutivo di Thermo Fisher Scientific, ha presentato un Modulo 4 che segnala quattro cessioni di azioni ordinarie dell'emittente in data 08/28/2025. Ciascuna operazione è riportata con Transaction Code F e un prezzo per azione di $489.74. Le diminuzioni segnalate sono di 145.051, 162.457, 176.478 e 114.106 azioni, con una detenzione beneficiaria finale di 18,730.8026 azioni dopo l'ultima vendita. Il documento indica l'inclusione di 49.871 azioni acquisite tramite il piano di acquisto azionario per dipendenti il 15 maggio 2025. Il Modulo 4 è stato firmato da un procuratore (attorney-in-fact) per conto del Sig. Shafer in data 09/02/2025. Il documento identifica il Sig. Shafer come dirigente (Executive Vice President) dell'emittente.

Michael D. Shafer, Vicepresidente Ejecutivo de Thermo Fisher Scientific, presentó un Formulario 4 que revela cuatro enajenaciones de acciones ordinarias del emisor el 08/28/2025. Cada operación figura con Transaction Code F y un precio por acción de $489.74. Las reducciones declaradas son de 145.051, 162.457, 176.478 y 114.106 acciones, dejando una tenencia beneficiaria final de 18,730.8026 acciones tras la última venta informada. La presentación señala la inclusión de 49.871 acciones adquiridas bajo el plan de compra de acciones para empleados el 15 de mayo de 2025. El Formulario 4 fue firmado por un apoderado (attorney-in-fact) en nombre del Sr. Shafer el 09/02/2025. El documento identifica al Sr. Shafer como funcionario (Executive Vice President) del emisor.

Michael D. Shafer, Thermo Fisher Scientific의 총괄 부사장은 08/28/2025자 Form 4를 제출하여 발행사의 보통주 4건의 처분을 공시했습니다. 각 거래는 Transaction Code F로 보고되었고 주당 가격은 $489.74입니다. 보고된 주식 감소량은 각각 145.051, 162.457, 176.478 및 114.106주이며, 마지막 매도 후 최종 실소유지는 18,730.8026주입니다. 서류에는 2025년 5월 15일 직원 주식매입계획으로 취득한 49.871주가 포함되어 있다고 기재되어 있습니다. Form 4는 09/02/2025에 Shafer 씨를 대신해 법정대리인(attorney-in-fact)이 서명했습니다. 문서는 Shafer 씨를 발행사의 임원(Executive Vice President)으로 명시하고 있습니다.

Michael D. Shafer, vice‑président exécutif de Thermo Fisher Scientific, a déposé un Formulaire 4 révélant quatre cessions d'actions ordinaires de l'émetteur le 08/28/2025. Chaque opération est indiquée avec le Transaction Code F et un prix par action de $489.74. Les diminutions signalées sont de 145.051, 162.457, 176.478 et 114.106 actions, laissant une détention bénéficiaire finale de 18,730.8026 actions après la dernière vente déclarée. le dépôt précise l'inclusion de 49.871 actions acquises dans le cadre du plan d'achat d'actions pour salariés le 15 mai 2025. Le Formulaire 4 a été signé le 09/02/2025 par un mandataire (attorney-in-fact) au nom de M. Shafer. Le document identifie M. Shafer comme dirigeant (Executive Vice President) de l'émetteur.

Michael D. Shafer, Executive Vice President von Thermo Fisher Scientific, reichte ein Formular 4 ein, das vier Veräußerungen von Stammaktien des Emittenten am 08/28/2025 offenlegt. Jede Transaktion ist mit Transaction Code F und einem Preis von $489.74 pro Aktie angegeben. Die gemeldeten Aktienminderungen betragen 145.051, 162.457, 176.478 und 114.106 Aktien, wobei nach dem letzten gemeldeten Verkauf ein finaler wirtschaftlicher Besitz von 18,730.8026 Aktien verbleibt. Die Einreichung vermerkt die Einbeziehung von 49.871 Aktien, die am 15. Mai 2025 über den Mitarbeiter-Aktienkaufplan erworben wurden. Das Formular 4 wurde am 09/02/2025 von einem Bevollmächtigten (attorney-in-fact) im Namen von Herrn Shafer unterzeichnet. Das Dokument führt Herrn Shafer als leitenden Angestellten (Executive Vice President) des Emittenten auf.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shafer Michael D

(Last) (First) (Middle)
168 THIRD AVENUE

(Street)
WALTHAM MA 02451

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
THERMO FISHER SCIENTIFIC INC. [ TMO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Executive Vice President
3. Date of Earliest Transaction (Month/Day/Year)
08/28/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/28/2025 F 145.051 D $489.74 19,183.8436(1) D
Common Stock 08/28/2025 F 162.457 D $489.74 19,021.3866 D
Common Stock 08/28/2025 F 176.478 D $489.74 18,844.9086 D
Common Stock 08/28/2025 F 114.106 D $489.74 18,730.8026 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Includes 49.871 shares acquired under the Issuer's employees' stock purchase plan on May 15, 2025.
/s/ Melodie T. Morin, Attorney-in-Fact for Michael D. Shafer 09/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did Thermo Fisher (TMO) report by Michael D. Shafer?

The filing reports four dispositions of Thermo Fisher common stock by Michael D. Shafer on 08/28/2025, each shown with Transaction Code F at a per-share price of $489.74.

How many shares did Michael D. Shafer sell in the Form 4 filed for TMO?

The Form 4 lists dispositions of 145.051, 162.457, 176.478 and 114.106 shares on 08/28/2025, with a final beneficial ownership of 18,730.8026 shares.

Does the Form 4 state Michael D. Shafer's role at Thermo Fisher (TMO)?

Yes. The filing identifies Michael D. Shafer as an Executive Vice President of Thermo Fisher Scientific.

Was there any share acquisition disclosed in this Form 4 for TMO?

The explanatory note states the totals include 49.871 shares acquired under the issuer's employee stock purchase plan on May 15, 2025.

When was the Form 4 signed and by whom?

The Form 4 bears the signature of an attorney-in-fact, Melodie T. Morin, on 09/02/2025 on behalf of Michael D. Shafer.
Thermo Fishr Sci

NYSE:TMO

TMO Rankings

TMO Latest News

TMO Latest SEC Filings

TMO Stock Data

186.06B
376.94M
0.16%
91.85%
0.98%
Diagnostics & Research
Measuring & Controlling Devices, Nec
Link
United States
WALTHAM